» Articles » PMID: 27093997

[Effects of Pre-immunosupressive Therapy Iron Overload on Hematologic Response of Severe Aplastic Anemia]

Overview
Specialty Hematology
Date 2016 Apr 21
PMID 27093997
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the effects of serum ferritin (SF) and iron overload (IO) pre-immunosupressive treatment (IST) on hematologic response of severe aplastic anemia (SAA/VSAA) patients treated with IST.

Methods: 257 SAA/VSAA patients who underwent first-line IST from Feb, 2003 to Dec, 2011 in Anemia Therapeutic Centre, Institute of Hematology and Blood Diseases Hospital were retrospectively analyzed, the status of SF before IST and the IO-affected factors were studied. The effects of IO on hematologic response of SAA/VSAA patients were evaluated as well.

Results: The median level of SF of 257 patients was 387 (6-2 004) μg/L. 36 patients (14%) had IO, including 20 SAA and 16 VSAA patients. According to univariate logistical regression analyses, IO was influenced by age>14 years (P=0.010) and blood transfusion (P<0.001). The multivariate logistic regression analysis showed that blood transfusion [P=0.001, OR=0.218 (95% CI 0.092-0.520)] was the only independent prognostic factor. SAA (but not for VSAA) patients with IO had much lower hematologic response rate in 6 month after IST (P=0.037). Absolute reticulocyte count and IO correlated with response at 6 month by univariate logistical regression analysis (P=0.014, 0.037). The multivariate logistic regression analysis showed that IO [P=0.021, OR=4.092 (95% CI 1.235-13.563)], ARC ≥20×10(9)/L [P=0.040, OR=2.743 (95% CI 1.049-7.175)] were independent prognostic factors.

Conclusion: 84.8% patients had high serum ferritin before IST, and 14.0% reached IO. Adult and more blood transfusion caused IO more likely. IO correlated with response at 6 month, and was independent prognostic factor.

References
1.
Pawelec K, Salamonowicz M, Panasiuk A, Leszczynska E, Krawczuk-Rybak M, Demkow U . Influence of Iron Overload on Immunosuppressive Therapy in Children with Severe Aplastic Anemia. Adv Exp Med Biol. 2015; 866:83-9. DOI: 10.1007/5584_2015_148. View

2.
Marsh J, Ball S, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith E . Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009; 147(1):43-70. DOI: 10.1111/j.1365-2141.2009.07842.x. View

3.
Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y . The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2011; 95(2):149-59. DOI: 10.1007/s12185-011-0988-3. View

4.
Baumelou E, Guiguet M, Mary J . Epidemiology of aplastic anemia in France: a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1993; 81(6):1471-8. View

5.
Cappellini M, Porter J, El-Beshlawy A, Li C, Seymour J, Elalfy M . Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2009; 95(4):557-66. PMC: 2857545. DOI: 10.3324/haematol.2009.014696. View